Skip to NavigationSkip to content

Results released from first clinical trial using Danoprevir to treat COVID-19

Published on 25/03/20 at 12:14pm

The first clinical trial using danoprevir (Ganovo) in treating COVID-19 has released its results, showing that it is safe and well tolerated in patients.

The data was published in medRxiv, and the trial saw 19 patients in a 4 to 12-day treatment of danoprevir combined with ritonavir.  After this initial treatment, the first negative test occurred at a median of 2 days and ranged from 1 to 8 days. CT scans revealed that the obvious absorption rate occurred at a median of 3 days ranging from 2 to 4 days.

Eleven patients were discharged from the hospital after they met all four of these conditions: normal body temperature for 3 days, improved respiratory symptoms, lung imaging showing absorption and recovery of acute exudative lesion and two consecutive RT-PCR negative tests of SARS-CoV-2 nucleotide acid.

Dr. Jinzi  Wu, Chairman and CEO of Ascletis, commented on the results: “We are pleased that the first clinical study using Ganovo®(danoprevir) to treat COVID-19 patients was published in medRxiv. Ascletis is proud of repurposing our HCV drug, danoprevir, as a potential therapeutic option for COVID-19.”

Conor Kavanagh

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches